glp-1 announcement New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our GLP-1 Pipeline Update: February 2026

Instead, its a delicate, white puck or loose powder at the bottom of a vacuum-sealed glass vial

doi:10.1053/j.ajkd.2016.10.037 10 Li G, Zhou CL, Ba YM, et al

Short-chain acylcarnitine levels were decreased in urinary and tissue of RA patients compared with control subjects 45

The high degree of tumor heterogeneity and adaptive cellular signaling plasticity, selection pressure, and clonal evolution substantially contribute to the resistance to molecularly targeted therapy including anti-IGF/IGF-IR agents [191]

Likewise, reduced dehydroascorbic acid (an oxidized form of ascorbic acid) combined with increased threonic acid (a major breakdown product of ascorbic acid) levels in the CSF indicates a change in oxidative stress response: dehydroascorbic acid has neuroprotective effects against free radicals in the brain, while threonic acid may interfere with the metabolism of ascorbic acid [137]

Here is an example of one study done in adolescents